Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy

NACompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 30, 2016

Primary Completion Date

April 2, 2018

Study Completion Date

June 20, 2018

Conditions
Central Serous Chorioretinopathy
Interventions
DEVICE

R:GEN Selective Retina Therapy

Selective Retina Therapy (SRT) is the treatment method using innovative laser technology with the wavelength absorbed by melanosomes such as laser photocoagulation, but due to short pulse width (1.7 µs) with 100 Hz repetition rate, Retinal Pigment Epithelium (RPE) cells may be destroyed only through the generation of microbubble around melanosomes (photomechanical action), and no thermal damage of normal cells or tissues may occur in the surrounding tissues. SRT influences the RPE wound healing, including migration and proliferation of RPE cells, which treats CSC in the mechanism of recovering RPE. Once RPE is recovered, the sub-retinal fluid may be pumped out and retinal function again recovered. Moreover, previous studies showed that SRT may stimulate a moderate increase of activated metalloproteinase (MMP), leading to the improvement of Bruch's membrane's transport property.

Trial Locations (6)

Unknown

Seoul National University Bundang Hospital, Seongnam-si

Korea University Anam hospital, Seoul

Nune Eye Hospital, Seoul

Seoul National University Hospital, Seoul

The Catholic University of Korea Seoul ST.Mary's Hospital, Seoul

The Catholic University of Korea Yeouido St.Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

LUTRONIC Corporation

INDUSTRY